E-mail Article

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.

* From Email:

* To Email:

To Email:

Email Subject Line:

Comments:

A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer

Chi KN et al. – Figitumumab is biologically active in prostate cancer. Prostate–specific antigen (PSA) declines in treatment–naive patients were observed, potentially mediated by insulin–like growth factor 1 receptor (IGF–IR) effects on androgen receptor expression. These results support the clinical relevance of IGF–IR signaling in prostate cancer and justify further clinical trials. [more...]

Clinical Cancer Research

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Internal Medicine Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?